GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lonza Group Ltd (OTCPK:LZAGY) » Definitions » Shares Buyback Ratio %

Lonza Group (Lonza Group) Shares Buyback Ratio % : 2.91 (As of Apr. 30, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Lonza Group Shares Buyback Ratio %?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Lonza Group's current shares buyback ratio was 2.91%.

Lonza Group Shares Buyback Ratio % Historical Data

The historical data trend for Lonza Group's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lonza Group Shares Buyback Ratio % Chart

Lonza Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.06 0.01 0.13 -0.12 2.91

Lonza Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 - -0.12 - 2.91

Lonza Group Shares Buyback Ratio % Calculation

Lonza Group's Shares Buyback Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2022 ) - Shares Outstanding (EOP) (A: Dec. 2023 )) / Shares Outstanding (EOP) (A: Dec. 2022 )
=(742.816 - 721.166) / 742.816
=2.91%

Lonza Group's Shares Buyback Ratio for the quarter that ended in Dec. 2023 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Jun. 2023 ) - Shares Outstanding (EOP) (A: Dec. 2023 )) / Shares Outstanding (EOP) (A: Jun. 2023 )
=(742.816 - 721.166) / 742.816
=2.91%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lonza Group Shares Buyback Ratio % Related Terms

Thank you for viewing the detailed overview of Lonza Group's Shares Buyback Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lonza Group (Lonza Group) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lonza Group Ltd (OTCPK:LZAGY) » Definitions » Shares Buyback Ratio %
Comparable Companies
XSWX:EMMN XSWX:ARYN XSWX:ORON XSWX:BARN XSWX:BELL XSWX:GMI XSWX:HOCN XSWX:GALD TSE:2309 TMO DHR IQV IDXX A MTD ICLR ILMN WAT SHSE:603259 LH
Traded in Other Exchanges
LZAGF:USA LONN:Mexico LONNz:UK LO3A:Germany LONNE:Switzerland LONN:Switzerland
Address
Muenchensteinerstrasse 38, Basel, CHE, CH-4002
Website
https://www.lonza.com
Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.